Syneos Health, Inc. provides biopharmaceutical outsourcing solutions company in North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America. It operates through two segments, Clinical Solutions and Commercial Solutions. The Clinical Solutions segment offers various services spanning Phases I to IV of clinical development, including full service global studies, as well as individual service offerings, such as clinical monitoring, investigator recruitment, patient recruitment, data management, and study startup to assist customers with their drug development process. The Commercial Solutions segment provides commercialization services comprising deployment solutions; communications solutions, such as public relations, advertising, and medical communications; and consulting services. Its customers include small, mid-sized, and large companies in the pharmaceutical, biotechnology, and medical device industries. Syneos Health, Inc. has a partnership with VBI Vaccines Inc. for the commercialization of 3-antigen prophylactic hepatitis B vaccine in the United States, Europe, and Canada, which is in pending regulatory approvals. The company was formerly known as INC Research Holdings, Inc. and changed its name to Syneos Health, Inc. in January 2018. Syneos Health, Inc. was incorporated in 2010 and is headquartered in Morrisville, North Carolina
IPO Year: 2014
Exchange: NASDAQ
Website: syneoshealth.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/13/2023 | $30.00 → $28.00 | Neutral → Underweight | JP Morgan |
| 1/17/2023 | $30.00 → $25.00 | Overweight → Underweight | Barclays |
| 1/13/2023 | $25.00 | Overweight → Underweight | Barclays |
| 12/14/2022 | $66.00 → $38.00 | Buy → Neutral | Mizuho |
| 11/7/2022 | $55.00 → $27.00 | Outperform → In-line | Evercore ISI |
| 10/18/2022 | $85.00 → $53.00 | Overweight → Neutral | JP Morgan |
| 9/14/2022 | Buy → Neutral | Guggenheim | |
| 9/7/2022 | $68.00 | Neutral | UBS |
| 5/24/2022 | $81.00 | Buy | Guggenheim |
| 4/25/2022 | $101.00 → $75.00 | Buy → Hold | Jefferies |
15-12G - Syneos Health, Inc. (0001610950) (Filer)
8-K - Syneos Health, Inc. (0001610950) (Filer)
S-8 POS - Syneos Health, Inc. (0001610950) (Filer)
S-8 POS - Syneos Health, Inc. (0001610950) (Filer)
S-8 POS - Syneos Health, Inc. (0001610950) (Filer)
S-8 POS - Syneos Health, Inc. (0001610950) (Filer)
25-NSE - Syneos Health, Inc. (0001610950) (Subject)
8-K - Syneos Health, Inc. (0001610950) (Filer)
8-K - Syneos Health, Inc. (0001610950) (Filer)
8-K - Syneos Health, Inc. (0001610950) (Filer)
4 - Syneos Health, Inc. (0001610950) (Issuer)
4 - Syneos Health, Inc. (0001610950) (Issuer)
4 - Syneos Health, Inc. (0001610950) (Issuer)
4 - Syneos Health, Inc. (0001610950) (Issuer)
4 - Syneos Health, Inc. (0001610950) (Issuer)
4 - Syneos Health, Inc. (0001610950) (Issuer)
4 - Syneos Health, Inc. (0001610950) (Issuer)
4 - Syneos Health, Inc. (0001610950) (Issuer)
4 - Syneos Health, Inc. (0001610950) (Issuer)
4 - Syneos Health, Inc. (0001610950) (Issuer)
JP Morgan downgraded Syneos Health from Neutral to Underweight and set a new price target of $28.00 from $30.00 previously
Barclays downgraded Syneos Health from Overweight to Underweight and set a new price target of $25.00 from $30.00 previously
Barclays downgraded Syneos Health from Overweight to Underweight and set a new price target of $25.00
Mizuho downgraded Syneos Health from Buy to Neutral and set a new price target of $38.00 from $66.00 previously
Evercore ISI downgraded Syneos Health from Outperform to In-line and set a new price target of $27.00 from $55.00 previously
JP Morgan downgraded Syneos Health from Overweight to Neutral and set a new price target of $53.00 from $85.00 previously
Guggenheim downgraded Syneos Health from Buy to Neutral
UBS initiated coverage of Syneos Health with a rating of Neutral and set a new price target of $68.00
Guggenheim initiated coverage of Syneos Health with a rating of Buy and set a new price target of $81.00
Jefferies downgraded Syneos Health from Buy to Hold and set a new price target of $75.00 from $101.00 previously